



April 26, 2016

Integra LifeSciences Announces Agreement with AlloSource® to Commercialize HuMend™, Human Acellular Dermal Matrix

PLAINSBORO, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holding Corporation](#) (NASDAQ:IART), a leading global medical technology company, today announced its entry into an agreement with AlloSource®, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing.

Under the agreement, Integra gains access to acellular dermal matrices derived from donated human dermis, along with rights to market these matrices in a subset of plastic and reconstructive soft tissue repair procedures. In particular, Integra's new product line, marketed under the name HuMend™ Acellular Dermal Matrix, will allow Integra to offer soft tissue repair solutions for patients undergoing plastic reconstructive procedures, which may include tendon protection, abdominal wall reconstruction, breast reconstruction, and other plastic and reconstructive procedures. Integra expects to launch HuMend™ ADM in mid-2016 to hospitals throughout North America.

"This agreement reflects Integra's commitment to offer our customers and patients a broad array of soft tissue repair solutions that help improve patient outcomes," said Mark Augusti, President of Integra's Orthopedics and Tissue Technologies business.

"We are excited about the expansion of our business relationship with Integra and are honored to work with a company that shares our commitment to clinicians and helping donated tissue reach more patients," said Thomas Cycyota, AlloSource's president and CEO.

Integra looks forward to the commercial release of the product and investing in clinical evidence to pave the way for patient and payer access.

About Integra

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.

About AlloSource

AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource's products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world's largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country's most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org, or our educational website, allograftpossibilities.org.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Company

Investors

Angela Steinway
609-936-2268
angela.steinway@integralife.com

Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com

Media

Gianna Sabella
609-775-8553
gianna.sabella@integralife.com